Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of staphylococcus aureus bacteremia

Clinical Infectious Diseases

Volumn 57, Issue 9, 2013, Pages 1225-1233

  López Cortés, Luis E ^a   Del Toro, Maria Dolores ^a,b   Gálvez Acebal, Juan ^a,b   Bereciartua Bastarrica, Elena ^c   Fariñas, María Carmen ^d   Sanz Franco, Mercedes ^e   Natera, Clara ^f   Corzo, Juan E ^g   Lomas, José Manuel ^h   Pasquau, Juan ⁱ   Del Arco, Alfonso ^j   Martínez, María Paz ^k   Romero, Alberto ^l   Muniain, Miguel A ^a,b,m   De Cueto, Marina ^a,b   Pascual, Álvaro ^a,b,m   Rodríguez Baño, Jesús ^a,b,m   Velasco, Carmen ^m   Caballero, Francisco Javier ^m   Montejo, Miguel ^c   Calvo, Jorge ^c   Aller Fernández, Marta ^d   Martínez, Luis ^g   Rojo, María Dolores ^g   Manzano Gamero, Victoria ^g   more..

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL DE CRUCES   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e HOSPITAL SAN PEDRO   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^h HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^j HOSPITAL COSTA DEL SOL   (Spain)

^k Hospital de Torrecardenas   (Spain)

^l HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

^m UNIVERSITY OF SEVILLE   (Spain)

more..

Author keywords

bacteremia; bloodstream infections; clinical management; intervention; Staphylococcus aureus

Indexed keywords

CLOXACILLIN; VANCOMYCIN;

ARTICLE; BLOOD CULTURE; CLINICAL INDICATOR; EVIDENCE BASED MEDICINE; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; INFECTION CONTROL; INTERVENTION STUDY; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; QUASI EXPERIMENTAL STUDY; STAPHYLOCOCCAL BACTEREMIA; SYSTEMATIC REVIEW; TREATMENT DURATION;

BACTEREMIA; BLOODSTREAM INFECTIONS; CLINICAL MANAGEMENT; INTERVENTION; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CASE MANAGEMENT; GUIDELINE ADHERENCE; HUMANS; SPAIN; STAPHYLOCOCCAL INFECTIONS; SURVIVAL ANALYSIS; TERTIARY CARE CENTERS; TREATMENT OUTCOME;

EID: 84886879355     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit499     Document Type: Article

References (40)

1. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 2004; 50:59-69.
2. Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163:2066-72.
3. Lesens O, Methlin C, Hansmann Y, et al. Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: A prospective study using the Charlson weighted index of comorbidity. Infect Control Hosp Epidemiol 2003; 24:890-6.
4. Lesens O, Hansmann Y, Brannigan E, et al. Positive surveillance blood culture is a predictive factor for secondary metastatic infection in patients with Staphylococcus aureus bacteraemia. J Infect 2004; 48:245-52.
5. Wyllie DH, Crook DW, Peto TE. Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: Cohort study. BMJ 2006; 333:281.
6. Liu C, Bayer A, Cosgrove SE, Daum RS, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:285-92.
7. Gudiol F, Aguado JM, Pascual A, et al. Consensus document for the treatment of bacteremia and endocarditis caused by methicillinresistant Staphylococcus aureus. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Enferm Infecc Microbiol Clin 2009; 27:105-15.
8. Rodríguez-Baño J, de Cueto M, Retamar P, et al. Current management of bloodstream infections. Expert Rev Anti Infect Ther 2010; 8:815-29.
9. Fowler VG Jr, Sanders L, Sexton D, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: Experience with 244 patients. Clin Infect Dis 1998; 27:478-86.
10. Jenkins TC, Price CS, Sabel AL, et al. Impact of routine infectious diseases service consultation on the evaluation, management, and outcomes of Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:1000-8.
11. Lahey T, Shah R, Gittzus J, et al. Infectious diseases consultation lowers mortality from Staphylococcus aureus bacteremia. Medicine (Baltimore) 2009; 88:263-7.
12. Rieg S, Peyerl-Hoffmann G, de With K, et al. Mortality of Staphylococcus aureus bacteremia and infectious diseases specialist consultation: A study of 521 patients in Germany. J Infect 2009; 59:232-9.
13. Honda H, Krauss M, Jones J, et al. The value of infectious diseases consultation in Staphylococcus aureus bacteremia. Am J Med 2010; 123:631-7.
14. Nagao M, Iinuma Y, Saito T, et al. Close cooperation between infectious disease physicians and attending physicians can result in better management and outcome for patients with Staphylococcus aureus bacteraemia. Clin Microbiol Infect 2010; 16:1783-8.
15. Robinson JO, Pozzi-Langhi S, Phillips M, et al. Formal infectious diseases consultation is associated with decreased mortality in Staphylococcus aureus bacteraemia. Eur J Clin Microbiol Infect Dis 2012; 31:2421-8.
16. Bone RC, Balk RA, Cerra FB, et al.; ACCP/SCCM Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest 2009; 136:e28.
17. Chang FY, MacDonald BB, Peacock JE, et al. A prospective multicenter study of Staphylococcus aureus bacteremia: Incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003; 82:322-32.
18. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 1987; 40:373-83.
19. Friedman ND, Kaye KS, Stout JE, et al. Health-care associated bloodstream infections in adults: A reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137:791-7.
20. Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial infections. Am J Infect Control 1998; 16:128-40.
21. Lodise TP, McKinnon PS, Swiderski L, et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36:1418-23.
22. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infec Dis 2008; 46:193-200.
23. Mitchell DH, Howden BP. Diagnosis and management of Staphylococcus aureus bacteraemia. Intern Med J 2005; 35:S17-24.
24. Fowler VG, Justice A, Moore C, et al. Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infec Dis 2005; 40:695-703.
25. Chang CF, Kuo BI, Chen TL, et al. Infective endocarditis in maintenance hemodialysis patients: Fifteen years? experience in one medical center. J Nephrol 2004; 17:228-35.
26. Reed SD, Friedman JY, Engemann JJ, et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin- susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2005; 26:175-83.
27. Ringberg H, Thoren A, Lilja B. Metastatic complications of Staphylococcus aureus septicemia: To seek is to find. Infection 2000; 28: 132-6.
28. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30:633-8.
29. Hartstein AI, Mulligan ME, Morthland VH, et al. Recurrent Staphylococcus aureus bacteremia. J Clin Microbiol 1992; 30:670-4.
30. Loza Fernández de Bobadilla E, Planes Reig A, Rodríguez- Creixems M. Hemocultivos. In: Procedimientos en Microbiología Clínica. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica, 2003. Available at: http://www.seimc.org/ documentos/protocolos/microbiologia. Accessed 14March 2013.
31. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. In: 20th informational supplement, June 2010. Update M100-S20-U.Wayne, PA: CLSI, 2010.
32. Minton J, Clayton J, Sandoe J, et al. Improving early management of bloodstream infection: A quality improvement project. BMJ 2008; 336:440-3.
33. Byl B, Clevenbergh P, Jacobs F, et al. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis 1999; 29:60-6.
34. Mainz J. Developing evidence-based clinical indicators: A state of the art methods primer. Int J Qual Health Care 2003; 15:i5-11.
35. Mainz J. Defining and classifying clinical indicators for quality improvement. Int J Qual Health Care 2003; 15:523-30.
36. Retamar P, Portillo MM, López-Prieto MD, et al. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: A propensity score-based analysis. Antimicrob Agents Chemother 2012; 56:472-8.
37. Bouza E, Sousa D, Muñoz P, et al. Bloodstream infections: A trial of the impact of different methods of reporting positive blood culture results. Clin Infect Dis 2004; 39:1161-9.
38. Harris AD, Bradham DD, Baumgarten M, et al. The use and interpretation of quasiexperimental studies in infectious diseases. Clin Infect Dis 2004; 38:1586-91.
39. Dryden M, Andrasevic AT, Bassetti M, et al. A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: Current clinical opinion and practice. Clin Microbiol Infect 2010; 16:3-30.
40. Shardell M, Harris AD, El-Kamary SS, et al. Statistical analysis and application of quasi experiments to antimicrobial resistance intervention studies. Clin Infect Dis 2007; 45:901-7.